SangCya

SangCya

Oncology A formulation of cyclosporine, an immunosuppressant for preventing rejection in transplants, rheumatoid arthritis, plaque psoriasis. See Cyclosporine.
Mentioned in ?
References in periodicals archive ?
They had secured an approval for a drug SangCya, saying it was similar to an old Novartis drug Sandimmun.
SangStat also announced it will terminate all clinical development programs for SangCya Oral Solution, CycloTech and diagnostic or monitoring products.
To this end, all clinical development programs for SangCya Oral Solution, CycloTech and diagnostic or monitoring products have been terminated.
In the suit, Novartis claimed that SangStat's oral solution, SangCya, employs a cyclosporine technology invented and patented by Novartis but not used in Novartis' innovative microemulsion product, Neoral (cyclosporine, USP MODIFIED).
Other factors that could cause actual results to differ materially include, without limitation, the expenses associated with and uncertainty related to the lawsuits pending against the MCA by Novartis with respect to SangCya oral solution, which could impact the regulatory approval of any cyclosporine capsule as well.
Novartis Pharmaceuticals Corporation has announced it has developed a monitoring program to support the "safe and responsible conversion" of transplant recipients on SangStat's SangCya (cyclosporine oral solution, USP [MODIFIED], to Neoral.
SangStat announced a withdrawal of SangCya oral solution from the US market on July 10, 2000.
The US Food and Drug Administration (FDA) announced on July 10 that the SangStat Medical Corporation, Fremont, CA, has agreed to recall all lots of SangCya oral solution because of clinical evidence that the generic drug is not bioequivalent to Novartis AG's Neoral oral solution when mixed with apple juice as recommended in its labeling.
SangStat launched SangCya in November 1998, Thymoglobulin(R) [Anti-thymocyte Globulin, (Rabbit)] in February 1999 and Celsior(R) cold storage solution in September 1999 in the United States.
The two companies also currently co-promote SangStat's liquid cyclosporine, SangCya.
The judge ruled that the Medicines Control Agency (MCA) acted properly in granting the SangCya Oral Solution marketing authorisation, ordered Novartis to pay MCA's costs incurred in defending the action, and denied Novartis' request to appeal the decision.